The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: A long term study
Autoimmune thyroid disease is a common complication of patients with chronic hepatitis C undergoing combination pegylated interferon-alpha and ribavirin treatment. A small proportion develops interferon-induced thyroiditis of which the long term natural history is unknown and how it compares with de novo thyroiditis.
The aim of the study is to determine the natural history of thyroid disease including antibody profile in this particular setting 36 months from the completion of therapy.
Methods: A cohort of 18 hepatitis C patients (mean age 45 +/- 8 years (standard deviation)) who developed exclusively thyroiditis in this setting was followed every 12 months after the completion of therapy for 36 months. Investigations included thyrotropin, free tetra-iodothyronine, free tri-iodothyronine levels and thyroid autoantibodies.
Results: None of the patients developed any long term thyroid disease.
Two patients had a prolonged hypothyroid phase of the thyroiditis early after the completion of treatment but recovered fully. The remaining 16 patients remained euthyroid.
Similarly, thyroid autoantibodies all declined and returned to reference range.
Conclusions: The long term natural history in this small series of interferon induced thyroiditis was benign. If a larger series confirms a similar outcome then there is no long term residual effect on thyroid function and follow-up testing would not be warranted.
Author: Huy TranTracey JonesElizabeth IannaGlenn Reeves
Credits/Source: Thyroid Research 2011, 4:2
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
No comments:
Post a Comment